<--- Back to Details
First PageDocument Content
Dendreon / Medicare / Medicine / Prostate cancer / Medicaid / Health / Government / Health economics / Healthcare reform in the United States / Federal assistance in the United States / Presidency of Lyndon B. Johnson
Date: 2015-03-04 02:57:41
Dendreon
Medicare
Medicine
Prostate cancer
Medicaid
Health
Government
Health economics
Healthcare reform in the United States
Federal assistance in the United States
Presidency of Lyndon B. Johnson

Medicare to pay for $93,000 prostate cancer drug

Add to Reading List

Source URL: phys.org

Download Document from Source Website

File Size: 26,31 KB

Share Document on Facebook

Similar Documents

About Advanced Prostate Cancer Treatment Options Resources Prostate Cancer Navigator

About Advanced Prostate Cancer Treatment Options Resources Prostate Cancer Navigator

DocID: 1oTjG - View Document

BIOTECH’S MOST RESPECTED NEWS SOURCE FOR MORE THAN 20 YEARS  THURSDAY MARCH 15, 2012  VOLUME 23 , NO. 51

BIOTECH’S MOST RESPECTED NEWS SOURCE FOR MORE THAN 20 YEARS THURSDAY MARCH 15, 2012 VOLUME 23 , NO. 51

DocID: 19ZND - View Document

Developing GMP IPS Lines - Identifying and Eliminating Roadblocks Mahendra Rao, M.D., Ph.D., (former) Director NIH CRM, Laboratory of Stem Cell Biology Chief,  The Path to Personalized Medicine

Developing GMP IPS Lines - Identifying and Eliminating Roadblocks Mahendra Rao, M.D., Ph.D., (former) Director NIH CRM, Laboratory of Stem Cell Biology Chief, The Path to Personalized Medicine

DocID: 14kRG - View Document

Medicare to pay for $93,000 prostate cancer drug

Medicare to pay for $93,000 prostate cancer drug

DocID: Rsxd - View Document

seen on the most sites For the second straight year, Janssen’s oral anticoagulant Xarelto was the most widely advertised branded drug on sites tracked by Kantar’s Evaliant tool (last year it tied for the top spot wit

seen on the most sites For the second straight year, Janssen’s oral anticoagulant Xarelto was the most widely advertised branded drug on sites tracked by Kantar’s Evaliant tool (last year it tied for the top spot wit

DocID: O0pR - View Document